Grace Therapeutics (GRCE) Reports $2.1M Quarterly Loss, Cash Runway Through 2028

Grace Therapeutics reported a net loss of $2.1M, or $0.11 per share, versus $0.9M, or $0.06, a year earlier. September 30 cash was $21.3M; the company expects funding for planned operations through calendar 2028.Material DetailsContext by AI AnalystThis is a mid-cycle regulatory execution update fo…